CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 163 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,912,393 | -18.9% | 759,898 | 0.0% | 3.21% | -10.5% |
| Q2 2023 | $25,783,339 | -5.7% | 759,898 | 0.0% | 3.59% | -8.8% |
| Q1 2023 | $27,341,130 | -19.4% | 759,898 | -0.2% | 3.93% | -25.5% |
| Q4 2022 | $33,935,509 | +58.6% | 761,398 | 0.0% | 5.28% | +43.0% |
| Q3 2022 | $21,403,000 | +4.3% | 761,398 | 0.0% | 3.69% | -32.6% |
| Q2 2022 | $20,527,000 | -20.8% | 761,398 | 0.0% | 5.48% | -2.3% |
| Q1 2022 | $25,933,000 | -11.9% | 761,398 | 0.0% | 5.61% | -2.1% |
| Q4 2021 | $29,420,000 | -28.4% | 761,398 | 0.0% | 5.72% | -43.4% |
| Q3 2021 | $41,108,000 | +119.0% | 761,398 | +35.6% | 10.12% | +160.3% |
| Q2 2021 | $18,773,000 | +62.3% | 561,398 | 0.0% | 3.89% | -10.7% |
| Q1 2021 | $11,565,000 | -36.6% | 561,398 | -46.1% | 4.36% | -31.1% |
| Q4 2020 | $18,245,000 | – | 1,041,398 | – | 6.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,017,524 | $20,961,000 | 7.56% |
| Octagon Capital Advisors LP | 561,398 | $11,565,000 | 4.36% |
| COMMODORE CAPITAL LP | 369,951 | $7,621,000 | 3.04% |
| Opaleye Management Inc. | 985,000 | $20,291,000 | 2.98% |
| VR Adviser, LLC | 1,240,610 | $25,557,000 | 2.77% |
| TSP Capital Management Group, LLC | 359,229 | $7,400,000 | 2.61% |
| RTW INVESTMENTS, LP | 3,908,947 | $80,524,000 | 1.26% |
| Ghost Tree Capital, LLC | 250,000 | $5,150,000 | 1.21% |
| Tri Locum Partners LP | 196,672 | $4,051,000 | 1.00% |
| Redmile Group, LLC | 3,387,788 | $69,788,000 | 0.98% |